Satralizumab 120 mg
MN42928
Approved small_molecule terminated
Quick answer
Satralizumab 120 mg for Neuromyelitis Optica Spectrum Disorder is a Approved program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hoffmann-La Roche
- Indication
- Neuromyelitis Optica Spectrum Disorder
- Phase
- Approved
- Modality
- small_molecule
- Status
- terminated